Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.



Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVID. That sounds great!


Read more about it


Photo Credit: Leohoho

0 views0 comments